All Articles
Showing 61–72 of 167 articles.
Resistance Training Associated with Modest Testosterone Increases and Improved Metabolic Markers in Middle-Aged Men, Synthesis Finds
Synthesis of clinical studies indicates that middle-aged men see temporary testosterone increases after resistance…
Read More →Pooled Data Link Regular Resistance Exercise to Modest Improvements in Serum Testosterone and Insulin Sensitivity
Evidence Synthesis Examines Resistance Training Effects on Testosterone and Metabolic Markers in Middle-Aged Men
Read More →FDA Authorizes Updated mRNA COVID-19 Vaccines Targeting KP.2 Variant for 2024-2025 Season
FDA Authorizes Updated Monovalent COVID-19 Vaccines Targeting KP.2 for 2024-2025 Season
Read More →CDC Report Details Four-Year Suicide Trends in U.S. Men by Industry and Demographics
The MMWR report from the CDC found that suicide rates among men aged 25 to 64 increased from 2019 to 2023. Rates…
Read More →Accuracy and Real-World Performance of Consumer Wearables in Male Cardiovascular Monitoring
Large trials supported by NIH resources tested smartwatches for atrial fibrillation detection in daily life. One study…
Read More →Answering Key Questions from the Uspstf Evidence Review on PSA-Based Screening
The USPSTF concludes with moderate certainty that PSA-based screening for prostate cancer in men ages 55-69 offers a…
Read More →FDA and CDC Clear Reformulated mRNA COVID-19 Vaccines for Fall 2024 Use
FDA Authorizes Updated 2024-2025 COVID-19 Vaccines Targeting KP.2 Lineage
Read More →FDA Clearance Pathways and Evidence for Cardiovascular Wearables
The FDA evaluates consumer wearables that monitor for signs of atrial fibrillation through its Digital Health Center…
Read More →Uspstf Updates Statin Guidance for Adults Ages 40–75 at Risk of Cardiovascular Disease
The U.S. Preventive Services Task Force updated its recommendation on statin use for primary prevention of…
Read More →FDA Detects Hidden PDE5 Inhibitors in OTC Male Enhancement Products
FDA Issues Safety Communication on Tainted Male Sexual Enhancement Supplements
Read More →FDA Labels, NEJM Trial Data, and NIH Findings on Semaglutide and Tirzepatide
Primary regulatory and clinical trial sources indicate that GLP-1 receptor agonists such as semaglutide produce…
Read More →What Recent NEJM Trial Data and Supporting Cohort Studies Show About HRT and Heart Risk
2023 TRAVERSE Trial Finds No Rise in Major Cardiovascular Events From Testosterone Therapy
Read More →